GlassScriptPhysician profile
Jose A Perez
NPI 1184624363
$2,457.15
in general payments reported to CMS, 2019-2025
28 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2021: $850 · 2022: $140 · 2023: $415 · 2024: $442 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $531.22 | 2021 | |
| Philips North America LLC | $265.90 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $251.79 | 2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $220.70 | 2023-2025 | Watchman Flx, General - Thrombectomy |
| Abbott Laboratories | $155.11 | 2019 | |
| Biotronik INC. | $128.79 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.08 | 2023-2024 | Lifevest |
| Acist Medical Systems, INC. | $111.69 | 2022-2024 | |
| Inari Medical, INC. | $100.22 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $92.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $86.40 | 2021-2023 | Verquvo |
| Pfizer INC. | $83.26 | 2022-2023 | |
| Cardiva Medical, INC. | $61.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.66 | 2019-2021 | |
| Atricure, INC. | $37.85 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $23.59 | 2023 | Cequa |
| Ekos Corporation | $21.83 | 2019 | |
| Cvrx, INC. | $21.34 | 2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.48 | 2022 | |
| Ardelyx, INC. | $17.79 | 2025 | Ibsrela |
| Agepha Pharma Fz LLC | $15.63 | 2024 | Lodoco |
| Esperion Therapeutics, INC. | $14.31 | 2022 | |
| Avinger INC. | $13.71 | 2021 | |
| Cook Medical LLC | $12.77 | 2023 | Evolution |
| Sanofi-Aventis U.S. LLC | $10.93 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.